Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
|
|
Actinium Pharmaceuticals, Inc. (ATNM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 12/30/2022 |
8-K
| Quarterly results |
| 12/09/2022 |
8-K
| Quarterly results |
| 10/31/2022 |
8-K
| Quarterly results |
| 06/29/2022 |
8-K
| Quarterly results |
| 04/13/2022 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 11/09/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/23/2021 |
8-K
| Quarterly results |
| 11/20/2020 |
8-K
| Appointed a new director |
| 10/28/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 08/14/2020 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits |
| 08/05/2020 |
8-K
| Quarterly results |
| 07/24/2020 |
8-K
| Quarterly results |
| 06/19/2020 |
8-K
| Other Events, Financial Statements and Exhibits |
| 06/18/2020 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Form of Pre-funded Warrant",
"Legal Opinion of Haynes and Boone, LLP",
"Form of Securities Purchase Agreement",
"Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering – June 16, 2020 – Actinium Pharmaceuticals, Inc. today announced that it intends to offer and sell shares of its common stock in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. Actinium intends to use the net proceeds from the offering to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate, Iomab-B, prepare and submit a Biologics License Application to the U.S. Food and Drug Administration and Marketing Authorization Application to the European Medicines Agen...",
"Actinium Pharmaceuticals, Inc. Announces Pricing of $25.0 Million Public Offering – June 16, 2020 – Actinium Pharmaceuticals, Inc. today announced the pricing of its previously announced public offering of 76,923,077 shares of its common stock at a price to the public of $0.325 per share of common stock . The aggregate gross proceeds from this offering are expected to be approximately $25.0 million, before deducting placement agent fees and other estimated offering expenses payable by Actinium. The offering is expected to close on or about June 19, 2020, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. Actinium intends to use the net proceeds from the offering to complete its ongoing pivotal, Phase 3 SI..." |
|
| 06/16/2020 |
8-K
| Other Events |
| 06/16/2020 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 05/15/2020 |
8-K
| Quarterly results |
| 05/05/2020 |
8-K
| Quarterly results |
| 05/05/2020 |
8-K
| Quarterly results |
| 04/24/2020 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 03/27/2020 |
8-K
| Quarterly results |
| 12/19/2019 |
8-K
| Quarterly results |
| 12/03/2019 |
8-K
| Other Events |
| 11/25/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/07/2019 |
8-K
| Other Events |
| 04/18/2019 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Underwriting Agreement, by and between Actinium Pharmaceuticals, Inc. and William Blair & Company, L.L.C",
"Form of Warrant",
"Opinion of The Matt Law Firm, PLLC",
"Press Release issued by Actinium Pharmaceuticals, Inc.",
"Press Release issued by Actinium Pharmaceuticals, Inc." |
|
| 03/12/2019 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year |
| 12/28/2018 |
8-K
| Entry into a Material Definitive Agreement |
| 12/26/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/21/2018 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 10/18/2018 |
8-K
| Quarterly results |
| 08/15/2018 |
8-K
| Changes in Registrant's Certifying Accountant |
| 05/01/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|